Phase II study of vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in patients with advanced transitional cell urothelial cancer (TCC) after platinum-based therapy—California Cancer Consortium/University of Pittsburgh NCI/CTEP-sponsored trial

Eric Cheung,David I. Quinn,Denice D. Tsao-Wei,Susan Groshen,Ana Aparicio,Przemyslaw Twardowski,Gurkamal S. Chatta,Primo N. Lara,David R. Gandara

Phase II study of vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in patients with advanced transitional cell urothelial cancer (TCC) after platinum-based therapy—California Cancer Consortium/University of Pittsburgh NCI/CTEP-sponsored trial

2008

Eric Cheung
David I. Quinn
Denice D. Tsao-Wei
Susan Groshen
Ana Aparicio
Przemyslaw Twardowski
Gurkamal S. Chatta
Primo N. Lara
David R. Gandara

16058 Background: There is no defined standard second-line therapy for patients (pts) with advanced TCC. Histone deacetylase inhibitors (HDACi) have anti-cancer activity in a variety of models incl...

Keywords:

Oncology
Cancer
Pathology
Suberoylanilide Hydroxamic Acid
Phases of clinical research
Vorinostat
Pharmacology
Medicine
Transitional Cell
Internal medicine
urothelial cancer
Histone deacetylase
Cancer research
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations